ANGPTL3 and familial hypercholesterolemia: In a randomized, double-blind, dose-escalation phase I clinical trial, healthy volunteers with elevated triglycerides and patients with familial hypercholesterolemia received subcutaneous injections of placebo or an antisense oligonucleotide targeting ANGPTL3 mRNA in a single dose or multiple doses weekly for 6 weeks [74].